Prostate Cancer

Prostate cancer is the most common cancer in men.

Approximately 1 in 8 men suffer from prostate cancer in their lifetime, with almost 50,000 diagnosed annually.

SwiftDX Protein Colour
Early prostate cancer detection

PSA: A Biomarker for the Early Detection of Prostate Cancer

PSA is widely-used by clinicians as an early indicator of possible prostate cancer. There are generally expected levels of PSA, based on patient age. It is, therefore, essential to use a test that can determine levels of PSA that are elevated above age-adjusted levels. Early and accurate screening quickly triages patients onto the correct diagnostic pathway.

At-Home PSA Testing

SwiftDx are developing threshold tests that will produce a positive result if the patient has PSA levels above the amount specified on that test.

These tests can be utilised in the following ways:


  • Screening for elevated PSA levels in men, using age-adjusted PSA levels
  • Screening in patients with a family history of prostate cancer, who may want to establish their own baseline and subsequently monitor themselves

Post-Treatment Monitoring

  • After prostate cancer treatment, patients could monitor their own PSA levels based on their expected baseline levels
SwiftDX Protein Mole

Early Prostate Cancer Detection

Need for early detection diagnostics

Men with prostate cancer have a 5-year survival rate of nearly 100% if caught early, which drops to 30% if discovered at a later stage of the disease

Current Rapid Diagnostics

Current LFAs are not sufficiently sensitive to discriminate between the different thresholds of PSA. The vast majority of PSA testing is performed in a lab setting

PSA testing Market

It is thought that the PSA testing global market will be worth more than USD 2.9B in 2027

SwiftDx Solution

SwiftDx will produce a high sensitivity PSA threshold diagnostic test using eAMP technology to provide early and more accurate diagnosis of prostate cancer.


Our affordable, easy to use and highly sensitive assay would be applicable in clinical settings as a point of care device and as a self-test application. Different age groups will be alerted to elevated PSA levels, based on existing NICE guidelines.